Metabolon Debuts New Client Portal at Bio-IT World Expo
MetaboLync™:A Cloud-based Solution for Sharing, Visualizing, and Analyzing Metabolomics Data
RESEARCH TRIANGLE PARK, N.C., Apr 29, 2014 (BUSINESS WIRE) -- Metabolon, Inc., a leader in metabolomics-driven biomarker discovery, announced today the debut and impending launch of MetaboLync, the company's innovative product offering which allows its clients to share, visualize, and explore metabolomics study results as a client directs. The company will unveil the capabilities of this new cloud-based software solution at the 2014 BIO-IT World Expo in Boston, Massachusetts on April 30th. Corey DeHaven, Metabolon's VP of Information Systems, is the visionary architect of the company's metabolomics data processing, analysis and storage systems. The company will exhibit, and Corey will provide, an introduction to the portal, including a demonstration of its capabilities, in an oral presentation within the Harnessing Data & Standards session.
"The MetaboLync client portal is our first informatics solution available to external users and further exemplifies our leadership position in metabolomics research and diagnostics. Extracting functional results from the information-rich metabolomics data stream is key to advancing our and our clients' research. This portal will empower users to more effectively visualize and navigate thru their own results interactively," commented Metabolon's President and CEO, John Ryals.
Informatics solutions have played an active and critical role in building Metabolon's leading biomarker discovery and metabolomics profiling platforms, DiscoveryHD4™ and TrueMass™. Metabolomics experiments generate a large amount of data, including both named and unnamed metabolites, group statistical analysis, and biological pathway annotations. Data visualization and analytical tools are required to aid in understanding the data, including relationships among detected metabolites and their effects on the underlying biology. MetaboLync leverages cloud-based resources and web service application program interfaces (APIs) to enable these functions. Equally important, this portal solution will enable Metabolon's clients to directly access their metabolomics study results as well as final reports interpreted by our biochemists that detail the biological significance of those results. We expect MetaboLync portal access will be available to clients for active research studies on May 15th when the company plans to migrate to a new website platform.
Metabolon is a world-leading, commercial-stage metabolomics company. Metabolomics is a rapidly evolving field of biochemical research and discovery focused on the measurement of small molecules involved in metabolism. Metabolon's proprietary metabolomics technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biological processes. Metabolon is pioneering the emerging field of global biochemical pathway analysis for biomarker discovery and the development of innovative diagnostic tests. The company's Metabolytics business uses its proprietary metabolomics technology to conduct sponsored studies for life sciences researchers in industry and academia, which provide insight into complex biochemical processes. Data from these studies are used to populate Metabolon's large and growing metabolomic information and pathway knowledge databases, which generate new product ideas for the company's expanding Diagnostics business. Through the complementary interplay of its Metabolytics and Diagnostics businesses, Metabolon has been able to develop and launch three innovative, non-invasive, and cost-effective diagnostic tests designed to address the large and underserved markets for urological cancers and obesity-related diseases such as type 2 diabetes . Metabolon's commercialized diagnostic tests and advancing product pipeline have the potential to provide physicians with better and more clinically actionable results in the detection, intervention, and prevention of urological cancers and obesity-related diseases than is currently available with existing diagnostic tests. For more information, visit www.metabolon.com , or email [email protected] or call 919-287-3364.
Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties, and assumptions. If any of these risks or uncertainties materializes or if any of these assumptions prove incorrect, the results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties, and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; our and our distributors' ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including regarding access, pricing and reimbursement of diagnostic tests; the strength of our intellectual property portfolio; our history of losses; whether we are able to achieve or sustain profitability; our highly competitive industry; our ability to compete effectively; security and privacy risks; and our ability to continue to innovate and provide products and services that are useful to our clients, among other risks, uncertainties, and assumptions.
SOURCE: Metabolon, Inc.